Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 2
2008 2
2009 1
2010 2
2011 4
2012 2
2013 2
2014 1
2015 1
2022 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover.
Oesterreich S, Henry NL, Kidwell KM, Van Poznak CH, Skaar TC, Dantzer J, Li L, Hangartner TN, Peacock M, Nguyen AT, Rae JM, Desta Z, Philips S, Storniolo AM, Stearns V, Hayes DF, Flockhart DA. Oesterreich S, et al. Breast Cancer Res Treat. 2015 Nov;154(2):263-73. doi: 10.1007/s10549-015-3608-8. Epub 2015 Nov 4. Breast Cancer Res Treat. 2015. PMID: 26536870 Free PMC article.
Aromatase inhibitor-induced modulation of breast density: clinical and genetic effects.
Henry NL, Chan HP, Dantzer J, Goswami CP, Li L, Skaar TC, Rae JM, Desta Z, Khouri N, Pinsky R, Oesterreich S, Zhou C, Hadjiiski L, Philips S, Robarge J, Nguyen AT, Storniolo AM, Flockhart DA, Hayes DF, Helvie MA, Stearns V. Henry NL, et al. Br J Cancer. 2013 Oct 29;109(9):2331-9. doi: 10.1038/bjc.2013.587. Epub 2013 Oct 1. Br J Cancer. 2013. PMID: 24084768 Free PMC article. Clinical Trial.
Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer.
Henry NL, Skaar TC, Dantzer J, Li L, Kidwell K, Gersch C, Nguyen AT, Rae JM, Desta Z, Oesterreich S, Philips S, Carpenter JS, Storniolo AM, Stearns V, Hayes DF, Flockhart DA. Henry NL, et al. Breast Cancer Res Treat. 2013 Apr;138(3):807-16. doi: 10.1007/s10549-013-2504-3. Epub 2013 Apr 2. Breast Cancer Res Treat. 2013. PMID: 23546553 Free PMC article. Clinical Trial.
Comparison of changes in the lipid profile of postmenopausal women with early stage breast cancer treated with exemestane or letrozole.
Bell LN, Nguyen AT, Li L, Desta Z, Henry NL, Hayes DF, Wolff AC, Stearns V, Storniolo AM, Flockhart DA; Consortium on Breast Cancer Pharmacogenomics (COBRA). Bell LN, et al. J Clin Pharmacol. 2012 Dec;52(12):1852-60. doi: 10.1177/0091270011424153. Epub 2011 Dec 15. J Clin Pharmacol. 2012. PMID: 22174434 Free PMC article. Clinical Trial.
A SNP in steroid receptor coactivator-1 disrupts a GSK3β phosphorylation site and is associated with altered tamoxifen response in bone.
Hartmaier RJ, Richter AS, Gillihan RM, Sallit JZ, McGuire SE, Wang J, Lee AV, Osborne CK, O'Malley BW, Brown PH, Xu J, Skaar TC, Philips S, Rae JM, Azzouz F, Li L, Hayden J, Henry NL, Nguyen AT, Stearns V, Hayes DF, Flockhart DA, Oesterreich S. Hartmaier RJ, et al. Mol Endocrinol. 2012 Feb;26(2):220-7. doi: 10.1210/me.2011-1032. Epub 2011 Dec 15. Mol Endocrinol. 2012. PMID: 22174377 Free PMC article.
Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age.
Desta Z, Kreutz Y, Nguyen AT, Li L, Skaar T, Kamdem LK, Henry NL, Hayes DF, Storniolo AM, Stearns V, Hoffmann E, Tyndale RF, Flockhart DA. Desta Z, et al. Clin Pharmacol Ther. 2011 Nov;90(5):693-700. doi: 10.1038/clpt.2011.174. Epub 2011 Oct 5. Clin Pharmacol Ther. 2011. PMID: 21975350 Free PMC article. Clinical Trial.
14 results